ImmuneOnco Slides 0.34% Amid Tech Rally, Investors Eye Long‑Term Immunotherapy Growth
ImmuneOnco Biopharma dips 10.5% amid HK market volatility, yet its diversified immuno‑oncology pipeline and equipment synergy offer a promising entry for cautious investors.
- IMMUNEONCO BIOPHARMACEUTIC-H
- China
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read